Related Experiment Video

Updated: Aug 30, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor

Ronald B Natale1

  • 1Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA. rnatale@csccc.salick.com

Clinical Lung Cancer
|December 4, 2003
PubMed

Insights

Epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitors like gefitinib show promise for solid tumors. Gefitinib is approved for advanced non-small-cell lung cancer (NSCLC) and may improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) plays a limited postembryonic role but is crucial in cancer progression.
  • Abnormal EGFR-tyrosine kinase (TK) activity drives tumor proliferation, angiogenesis, invasiveness, apoptosis resistance, and dedifferentiation.
  • Targeting EGFR is a key strategy in molecular therapy for solid tumors.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of EGFR-targeted therapies, specifically TK inhibitors.
  • To assess the role of gefitinib in treating advanced non-small-cell lung cancer (NSCLC).

Main Methods:

  • Development of monoclonal antibodies targeting the EGFR ligand-binding domain.
  • Utilization of small-molecule agents inhibiting the intracellular EGFR-TK domain.
  • Clinical trials with gefitinib and erlotinib in various tumor types, focusing on advanced NSCLC.

Main Results:

  • Gefitinib and erlotinib demonstrated antitumor activity and good tolerability in early clinical trials.
  • Gefitinib showed significant tumor responses and symptom relief in heavily pretreated advanced NSCLC patients.
  • Gefitinib received approval for third-line treatment of advanced NSCLC.

Conclusions:

  • EGFR-targeted therapies, particularly TK inhibitors like gefitinib, offer a viable treatment option for solid tumors.
  • Gefitinib's efficacy in advanced NSCLC supports its use in standard treatment or combination therapies.
  • Further integration of gefitinib with other molecular agents may enhance outcomes for NSCLC and other solid tumor patients.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...